Participation in research: the economic advantages in a haemophilia research population.
Wasserman
J
J
The University of Texas Health Science Center at Houston, Houston, Texas, USA. jwasserman@ped1.med.uth.tmc.edu
Ullman
M
M
Cantini
M
M
Moynihan
K
K
Hoots
W K
WK
D019380:Anti-HIV Agents / Q000191:economics / Q000627:therapeutic use; D002985:Clinical Protocols; D003363:Cost Control; D016527:Drug Costs; D005164:Factor IX / Q000191:economics / Q000627:therapeutic use; D005169:Factor VIII / Q000191:economics / Q000627:therapeutic use; D017048:Health Care Costs; D006467:Hemophilia A / Q000191:economics* / Q000821:virology; D002836:Hemophilia B / Q000191:economics / Q000821:virology; D006801:Humans; D011994:Recombinant Proteins / Q000191:economics / Q000627:therapeutic use; D012106:Research / Q000191:economics*
D019380:Anti-HIV Agents; D011994:Recombinant Proteins; D005169:Factor VIII; D005164:Factor IX